Selective agonist of the innate repair receptor (EPOR/CD131 heteromer) without binding the canonical EPOR — provides EPO's tissue-protective effects without erythropoiesis.
Reference facts
- Also known as
- Cibinetide, Helix B Surface Peptide
- Category
- Healing & Tissue Repair
- Mechanism of action
- Selective agonist of the innate repair receptor (EPOR/CD131 heteromer) without binding the canonical EPOR — provides EPO's tissue-protective effects without erythropoiesis.
- Targets
- EPOR/CD131
- Indications under research or approved
- Sarcoidosis-related small fibre neuropathy (Phase 2/3), Diabetic neuropathy (research)
- Regulatory status (reference entry)
- Investigational
- Half-life
- ~2 minutes (i.v.)
- Sequence
- QEQLERALNSS
- Sequence notes
- 11-residue peptide derived from helix B of erythropoietin (EPO).
- Molecular weight (Da)
- 1257
- Originator / sponsor
- Araim Pharmaceuticals
- First reported
- 2008
Primary References
Explore research articles about ARA-290
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.